Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27552476 | 0.79 | CA1 (0.44) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL26163088 | 0.77 | CA1 (0.42) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL10076880 | 0.77 | CA1 (0.42) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL22503265 | 0.77 | CA1 (0.42) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL22503294 | 0.77 | CA1 (0.42) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL8341773 | 0.76 | CA1 (0.41) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL22503267 | 0.76 | CA1 (0.41) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL7240710 | 0.74 | HDAC3 (0.43) | CA2CA1MMP2MMP9MMP12 | |
| SCHEMBL22503212 | 0.74 | PHF8 (0.43) | CA2CA1CA7CA13 | |
| SCHEMBL18969615 | 0.74 | CA1 (0.44) | CA2CA1MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | claimed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NR1H4, SLC10A1, CYP46A1 | CA2 794/4885CA1 124/4885MMP2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.